The WHO has bestowed an esteemed honor upon GC Biopharma, the leading biopharmaceutical provider in South Korea. On February 3rd, 2023, the WHO granted prequalification to the Ochang-based filling and finish plant, a major milestone for GC Biopharma and the people of South Korea.
GC Biopharma has established the largest filling and finish facility in South Korea, with state-of-the-art automation and single-use systems. This modern facility is capable of producing 300 million doses annually, enabling CMO of Drug Products (DP) for vaccines in both sterile vials and prefilled syringes, as well as non-vaccine filling, finishing and packaging. With its high-tech capabilities, this cutting-edge facility is changing the face of the drug production industry.
GC Biopharma has established a world-class production hub in Hwa-sun, South Korea, where they can manufacture their products to the highest global standards. Following this, they have built a vaccine plant to meet their growing global demand. With the PQ certification, they are now able to provide the highest quality products to their customers worldwide.
For the past three years, GGC Biopharma has been a steadfast supplier of seasonal flu vaccines, supplying more than 50 million doses of flu vaccines even during the COVID-19 pandemic. Working in partnership with the World Health Organization, Pan American Health Organization (PAHO) and UNICEF, GGC Biopharma has been instrumental in providing essential protection to millions of people from the threat of influenza.
GC Biopharma has created a remarkable production hub in Hwa-sun, South Korea, that can manufacture products to the highest global standards. Their state-of-the-art vaccine plant has been built to fulfill the rising global demand for their products. Thanks to their PQ certification, GC Biopharma can now guarantee the highest quality products to their customers all around the world.
For the past three years, GGC Biopharma has been a loyal provider of seasonal flu vaccines, ensuring that more than 50 million people receive the protection they need against influenza, even during the tumultuous COVID-19 pandemic. By working in collaboration with the World Health Organization, Pan American Health Organization (PAHO) and UNICEF, GGC Biopharma has been able to make a meaningful difference in the lives of millions of people, providing them with the essential safeguard of flu vaccinations.
For over 50 years, GC Biopharma has been at the forefront of vaccine production and supply, and now, President EC Huh, Ph.D. is proud to announce that the company is leveraging its expertise to make a positive contribution to global public health.
About GC Biopharma
GC Biopharma, formerly known as Green Cross Corporation, is an innovative biopharmaceutical company that has been providing life-saving and life-sustaining protein therapeutics and vaccines for over 50 years. Based in Yongin, South Korea, GC Biopharma is a leader in plasma protein and vaccine production, offering top-quality healthcare solutions to patients around the world.
At GC Biopharma, we are always looking to the future. Our management team is committed to providing the best possible outcomes and has expressed their current beliefs and expectations through forward-looking statements. Despite the potential risks and uncertainties, we are confident in our ability to deliver results that exceed expectations. We strive to keep all of our stakeholders informed of our progress and will continue to update or revise any forward-looking statements as required by law or stock exchange rule.